文献速递肾癌与肾肿瘤

替西罗莫司对比帕唑帕尼(TemPa)治疗具有不良预后特征的晚期透明细胞肾细胞癌患者:一项随机II期试验

Temsirolimus versus Pazopanib (TemPa) in Patients with Advanced Clear-cell Renal Cell Carcinoma and Poor-risk Features: A Randomized Phase II Trial.
PubMed 文献 · Eur Urol Oncol · 2019-07-02

这项随机II期试验在69例初治转移性肾细胞癌且以透明细胞特征为主、具有不良预后临床特征的患者中比较替西罗莫司与帕唑帕尼一线治疗。主要终点无进展生存期在替西罗莫司组为2.7个月、帕唑帕尼组为5.2个月(校正HR 1.36,95%CI 0.84-2.22;p=0.210),总生存期分别为7.1个月和11.9个月(校正HR 1.16,95%CI 0.70-1.93;p=0.558)。作者结论认为两药在该人群中活性有限,应不支持在此类患者中使用。

要点

  • 替西罗莫司组中位无进展生存期2.7个月,帕唑帕尼组5.2个月,差异未达统计学显著。
  • 替西罗莫司组中位总生存期7.1个月,帕唑帕尼组11.9个月,差异未达统计学显著。
  • 作者结论认为两药在不良风险透明细胞转移性肾细胞癌中活性有限,应不支持使用。

核心结论

  • 替西罗莫司和帕唑帕尼在不良风险透明细胞转移性肾细胞癌患者中活性有限,因此应不支持在该情形下使用。

研究设计与样本

  • 随机(1:1)II期试验,2012-2017年在一家学术癌症中心纳入69例初治转移性肾细胞癌患者,要求具有三个或以上短生存预测因素。
  • 允许在一线药物停用后交叉至另一种治疗。
  • 主要终点为无进展生存期,次要终点为总生存期、客观缓解率、安全性和患者报告结局。
  • 影像学缓解由盲法放射科医师评估。
  • 疗效结局按既往肾切除术状态、既往白细胞介素-2治疗和IMDC评分进行校正。

主要发现

  • 35例接受替西罗莫司一线治疗,34例接受帕唑帕尼一线治疗;总体72%按IMDC评分为不良风险。
  • 一线中位无进展生存期替西罗莫司组2.7个月 vs 帕唑帕尼组5.2个月(校正HR 1.36,95%CI 0.84-2.22;p=0.210)。
  • 中位总生存期替西罗莫司组7.1个月 vs 帕唑帕尼组11.9个月(校正HR 1.16,95%CI 0.70-1.93;p=0.558)。
  • 客观缓解率替西罗莫司组5.9% vs 帕唑帕尼组21.2%(校正OR 5.2,95%CI 0.9-29.3;p=0.062)。
  • 患者报告结局指标 favoring 帕唑帕尼;5例因不良事件停用一线治疗。

临床怎么用

  • 作者结论认为替西罗莫司和帕唑帕尼在不良风险透明细胞转移性肾细胞癌中活性有限,应不支持在该情形下使用。
  • 患者摘要指出多数患者生存期小于1年,提示对这些患者应优先考虑更有效的替代治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Temsirolimus has level 1 evidence for initial treatment of poor-risk patients with advanced renal cell carcinoma (mRCC), but its efficacy has not been directly compared with an antiangiogenic tyrosine kinase inhibitor (vascular endothelial growth factor receptor tyrosine kinase inhibitor [VEGFR TKi]) in this setting. OBJECTIVE: To evaluate temsirolimus versus pazopanib as first-line therapy in patients with mRCC, predominant clear-cell features, and clinical characteristics of a poor prognosis. DESIGN, SETTING, AND PARTICIPANTS: A randomized (1:1) phase II trial in 69 treatment-naïve mRCC patients and with three or more predictors of short survival for temsirolimus was conducted during 2012-2017 in a single academic cancer center. Crossover to the alternative treatment upon discontinuation of the first-line agent was permitted. INTERVENTION: Mechanistic target of rapamycin inhibitor temsirolimus and VEGFR TKi pazopanib. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The primary endpoint was progression-free survival (PFS), and the secondary endpoints were overall survival (OS), objective response rate (ORR), safety, and patient-reported outcomes (PROs). Radiographic response was assessed by blinded radiologists. Efficacy outcomes were adjusted by prior nephrectomy status, prior interleukin-2 treatment, and the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) score. RESULTS AND LIMITATIONS: Thirty-five patients received temsirolimus and 34 received pazopanib upfront; 72% overall had poor risk by IMDC. Median PFS in the first line was 2.7mo with temsirolimus and 5.2mo with pazopanib (adjusted hazard ratio [HR] 1.36, 95% confidence interval [CI] 0.84-2.22; p=0.210). Median OS was 7.1mo with temsirolimus and 11.9mo with pazopanib (adjusted HR 1.16, 95% CI 0.70-1.93; p=0.558), and ORRs were 5.9% and 21.2%, respectively (adjusted odds ratio 5.2, 95% CI 0.9-29.3; p=0.062). PRO measures favored pazopanib. Five patients discontinued first-line therapy due to adverse events. CONCLUSIONS: Temsirolimus and pazopanib had modest activity in patients with poor-risk clear-cell mRCC, and therefore their use should be discouraged in this setting. PATIENT SUMMARY: We evaluated outcomes of advanced renal cell carcinoma patients presenting with aggressive features when treated with temsirolimus or pazopanib as first-line therapy. Survival was <1yr for most, suggesting that more efficacious alternative treatments should be favored for these patients.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Tannir NM, Msaouel P, Ross JA, et al. Temsirolimus versus Pazopanib (TemPa) in Patients with Advanced Clear-cell Renal Cell Carcinoma and Poor-risk Features: A Randomized Phase II Trial. Eur Urol Oncol. 2019. PMID: 31272939. doi:10.1016/j.euo.2019.06.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。